相关临床试验
33
1 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1910
进行中（未招募）
1
3.0%
已完成
19
57.6%
招募中
1
3.0%
终止
1
3.0%
Unknown
11
33.3%
暂无批准数据
- Moffitt Cancer Center has been awarded a $22.4 million grant from the U.S. Department of War to lead groundbreaking studies and clinical trials for leptomeningeal disease, a devastating complication of breast and other cancers. - The competitive award is the only grant funded among 14 national applicants and will support four years of research and two clinical trials testing novel dendritic cell therapy and combination immunotherapy approaches. - Leptomeningeal disease is extremely deadly, often giving patients only two to five months to live, with breast cancer cells particularly drawn to the brain and spinal fluid where they can evade treatment. - The research aims to transform patient outcomes by training immune cells to recognize and attack tumor cells in the brain and spinal fluid, potentially extending survival from months to years.
- Researchers have developed drugs targeting KNDY neurons to treat reproductive system malfunctions, including infertility and menstrual issues. - One drug, developed following the discovery of KNDY neurons, has already received FDA approval for treating hot flashes by blocking neurokinin B (NKB). - Clinical trials are underway for additional drugs to address conditions like delayed puberty and PCOS, potentially revolutionizing treatment within five years. - The research, stemming from animal studies, exemplifies how understanding the brain's control of hormones can lead to innovative therapies.
